Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: Is there an ethnic disparity?

Cutaneous and Ocular Toxicology

Volumn 27, Issue 4, 2008, Pages 311-315

  Saif, Muhammad Wasif ^a   Sandoval, Amanda ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 FU; African Americans; Capecitabine; DPD; Ethnicity; Gastric cancer; Hand and foot syndrome; Rash

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; METHYLPREDNISOLONE SODIUM SUCCINATE; NORADRENALIN; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN;

AFRICAN AMERICAN; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SUBSTITUTION; ETHNIC DIFFERENCE; GASTRECTOMY; HAND FOOT SYNDROME; HAND PALM; HUMAN; MALE; MONOTHERAPY; NEUTROPHIL COUNT; POSTOPERATIVE PERIOD; RADIATION DOSE; SEPSIS; SKIN DISCOLORATION; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; AFRICAN AMERICANS; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; MALE; STOMACH NEOPLASMS;

EID: 57049184679     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.1080/15569520802355774     Document Type: Article

References (9)

1. Chu E, DeVita VT Jr, eds. Physicians' Cancer Chemotherapy Drug Manual; Boston, MA: Jones and Bartlett. 2006.
2. Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 2006; 6(4):288-296.
3. Johnson M, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001; 41:151-157.
4. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006; 12(18):5491-5495.
5. Narasimham P, Narasimhan S, Hitti IF, Rachita M. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of literature. Cutis 2004; 73(2):101-106.
6. Saif MW, Elfiky AA. Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. J Support Oncol 2007; 5(7):337-343.
7. Grau JJ, Caballero M, Monzó M, Muñoz-García C, Domingo-Domenech J, Navarro A, Conill C, Campayo M, Bombí JA. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol 2008; 98(2):130-134.
8. MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725-730.
9. Roche. 2008. http://www.rocheusa.com/products/xeloda. Last assessed on Aug 26, 2008.